Search

Your search keyword '"Krämer, Alwin"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Krämer, Alwin" Remove constraint Author: "Krämer, Alwin" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
175 results on '"Krämer, Alwin"'

Search Results

2. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

3. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

4. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

8. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

10. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

12. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

13. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

15. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

16. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

18. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

22. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

23. Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

24. Supplementary Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

25. Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie

30. Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

32. Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

33. Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

35. Supplementary Methods, Video Legends, Tables 1-2, Figures 1-8 from Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification, and Genome Maintenance

37. Supplementary Figure 2 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

38. Supplementary Figure 3 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

40. Supplementary Figure 5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

44. Supplementary Figure Legends 1-5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo

49. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

50. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution

Catalog

Books, media, physical & digital resources